Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

AstraZeneca

Generics, lack of flu pandemic lead to 13% drop in U.S. sales

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 3Q10

3Q Revenues: $7.9 billion (-4%)

3Q Earnings: $1.8 billion (-23%)

YTD Revenues: $24.7 billion (+3%)

YTD Earnings: $6.2 billion (-1%)

Comments: Generic competition in the U.S. for Arimidex, Pulmicort Respules and Toprol-XL, along with a lack of H1N1 pandemic vaccine revenue, led U.S. sales to drop 13% in 3Q10 to $3.2 billion. U.S. sales are down 5% YTD to $10.3 billion. Western Europe sales are up 3% and 4% for the quarter and YTD respectively, to $2.1 billion and $6.8 billion. Established rest-of-world sales are up 5%/7% to $1.3 billion and $3.7 billion, and emerging rest-of-world sales were up 14%/16% to $1.3 billion and $3.9 billion, respectively. Worldwide Crestor sales were up 20% to $1.4 billion for the quarter, and up 23% YTD to $4.1 billion. Arimidex sales plummeted 38% in 3Q10 to $284 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters